Contingent valuation of an inhaled delivery system for insulin.
Published: 2004
Language: eng
Number of pages: 143
Description: Results. Mean age of participants was 51.8 +/- 13.4. Seventy-seven had type-2, 19 had type-1 DM. Significantly more participants preferred INI over SCI (P &lt; 0.01). Mean monthly WTP for INI ($153,70 +/- $99.90) was significantly more than $50 monthly cost of SCI (P &lt; 0.01). Significantly more participants with type-2 DM and participants using oral antidiabetic drugs preferred INI (P &lt; 0.001). Those who did not use insulin were willing-to-pay significantly more than were insulin users (P &lt; 0.001). Multiple regression analysis showed that income was significantly associated with WTP for INI.Methods. A contingent valuation survey was administered to 96 DM outpatients at St. Michael's Hospital. Standardized information about INI and subcutaneous-insulin (SCI) was provided by video. Participants' product preference was asked and their WTP was elicited using "payment-scale" method.Purpose. To determine diabetic (DM) patients' willingness-to-pay (WTP) for inhaled insulin (INI).Conclusion. Diabetic patient prefer INI over CSI and are willing to pay a substantial amount for using it.
Notes: Adviser:  L. MacKeigan.

Thesis (M.Sc.)--University of Toronto, 2004.

Electronic version licensed for access by U. of T. users.

Source: Masters Abstracts International, Volume: 43-03, page: 0833.

MICR copy on microfiche (2 microfiches).